Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03232333 · ClinicalTrials.gov registry record
MIRODERM H2H DFU Study
A clinical trial, sponsored by Miromatrix Medical.
- Completed
- Registry status
- 53
- Enrollment target
NCT03232333: Completed study, sponsored by Miromatrix Medical.
NCT03232333 is a clinical trial that has completed, run by Miromatrix Medical. The registered enrollment target is 53 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03232333 has completed, sponsored by Miromatrix Medical.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
Study Summary
This study will assess the ability of MIRODERM to heal difficult diabetic foot ulcers within 12 weeks of treatment.
Primary Outcome
Percentage of participants with healed ulcers within 12 weeks of treatment
Interventions
- DEVICE Biologic wound graft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2017-07-21 |
| Est. Completion | 2018-09-20 |
What the finished NCT03232333 record still lists
NCT03232333 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Biologic wound graft is the first listed.
NCT03232333 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03232333 about?
NCT03232333 is a clinical study titled "MIRODERM H2H DFU Study". This study will assess the ability of MIRODERM to heal difficult diabetic foot ulcers within 12 weeks of treatment.
What is the current status of trial NCT03232333?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2017-07-21. Estimated completion is 2018-09-20.
What interventions are being tested in trial NCT03232333?
The interventions under investigation include: Biologic wound graft (DEVICE).
Who is sponsoring clinical trial NCT03232333?
This trial is sponsored by Miromatrix Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI